AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented

The 12-week study, investigated AMR101 as a treatment for patients with high triglycerides (greater than or equal to 200 and <500 mg/dL) who were also on statin therapy for elevated low-density lipoprotein cholesterol. Of 702 total patients, 514 (73%) had diabetes mellitus-2.
Read more

Posted in Type II Drugs